U.S. Markets closed

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
2.80-0.01 (-0.36%)
At close: 4:00PM EDT
People also watch
  • All GERNsters it is Friday. No it's not howdie doodie time. It's time to get ready for the big news release on Monday.

    If feel left out and I just wanted post some nonsense. Everybody else can do it. Why can't I. Just saying.
  • At the top of my page it says, 11,319 reactions on $GERN conversation. Depending on who you mute it might be different for U.

    Then I looked at William's posts and it says 6465 reactions. So 57% of the posts here on my Geron Conversation page are by William.

    No judgment here just saying. ;) ;)
  • My Take....JNJ would not embaress their reputation by listing a Drug on their Pipeline List of Blockbuster drugs on a WHIM....JMHO
  • Breakout day coming
  • insipid marango dance your black dance
    regurgitating your tedious repetitive rants
    living your life to suck hedgie boot
    thank baby Jesus I have you on mute.
  • If the shorts buy back all 34 million shorted GERN shares Monday GERN will close at over $50 a share.
  • We have entered into Phase 3 for IMERGE (They are recruiting participants): Here's what the current presentation from Geron says about the Part 1, Part 2 (Phase 3):
    - Part 1 (Phase 2) to evaluate safety and efficacy of imetelstat to advance to Part 2 based on positive assessment of
    benefit-risk profile in significant unmet medical need population
    - Part 2 (Phase 3) to compare imetelstat to placebo using an established regulatory endpoint

    Now here's what the IMERGE Trials data posted on Geron's web site says as of June 29:
    This study is currently recruiting participants. (It shows 46 locations are recruiting - I believe this is different than the 30 patients they recruited for Part 1)
    See Contacts and Locations
    Verified June 2017 by Janssen Research & Development, LLC
    Janssen Research & Development, LLC
    Information provided by (Responsible Party):
    Janssen Research & Development, LLC
    ClinicalTrials.gov Identifier:
    First received: October 27, 2015
    Last updated: June 29, 2017
    Last verified: June 2017
  • repost from seeking alpha

    So just take a look guys and gals:
    ® developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company,
    ® licensed from
    BTG International Ltd.,
    ® developed in collaboration with Millennium: The Takeda Oncology Company,
    ® licensed from
    Genmab A/S,
    ® licensed from Amgen Inc., and
    Imetelstat licensed from Geron Corporation
    This isn't an exercise in perfection. Look at that list folks!
    Maybe I'm reading more into it than it's worth, but LOOK AT THAT LIST!!!!
    Imetelstat mentioned in the same breath as Imbruvica?
  • Eventual Retirement, you've been posting in broken "Engrish" for at least seventeen years. Technology can't stop you from lying about "imet is already in Phase 3!", but you could at least be lying coherently. (There's a grammar checker on your computer already, you could use that too).


    Rosetta Stone® - Learn a New Language
    Learn to speak a new language with Rosetta Stone®.
  • NEW patent ?
    United States Patent 9,708,360
    Pongracz , et al. July 18, 2017
    Phosphorodiamidate backbone linkage for oligonucleotides

    This invention relates to antisense oligonucleotides comprising at least one N3'.fwdarw.P5' phosphorodiamidate linkage (NPN) in the backbone, and kits and pharmaceutical compositions thereof, useful for modulating gene expression involved in the pathogenesis of a disease. Also included are compounds useful as building blocks of said antisense oligonucleotides and methods of preparing said antisense oligonucleotides and building block compounds including NPN linkages.

    Inventors: Pongracz; Krisztina (Oakland, CA), Ramaseshan; Mahesh (Sunnyvale, CA)
    Name City State Country Type

    Geron Corporation
    Menlo Park
    Assignee: Geron Corporation (Menlo Park, CA)
    Family ID: 1000002711482
    Appl. No.: 14/498,872
    Filed: September 26, 2014
  • Phase 3 is creeping up on the Menlow Park brownie test lab fab 15 team.
  • I need some news, these student loans arent to get paid off just on my salary! Come on Chip, throw me something!!
  • Think of it this way. Buy 34 million shares of GERN stock tomorrow and see where GERN's price runs to. It will be somewhere north of $50 a share.
  • oh donkey dee donkey doo
    clutters the board with half wit spew
    lacks the brains to make the ^A^ fud team
    so he pulls his pud and blows out steam.
  • Very rough sales numbers of the JNJ listed Oncology drugs, from a Google search:
    Imbruvica - $2 billion
    Zytiga - $9 billion
    Velcade - $7 billion
    Darzalex - $9 billion
    Eprex and Procrit - $2 billion
    Imetelstat - TBD
  • From JNJ-webcast July 18, Billions in sales projections from pipeline opportunities- 2017 Strategic Partnerships, Collaborations & Licensing Arrangements: During the course of this morning’s presentations, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. Following is an acknowledgement of those relationships.
    IMBRUVICA® developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company, ZYTIGA® licensed from BTG International Ltd., VELCADE® developed in collaboration with Millennium: The Takeda Oncology Company, DARZALEX® licensed from GenmabA/S, PROCRIT®/EPREX® licensed from Amgen Inc., and Imetelstat licensed from Geron Corporation.
    The best news: the Menlow Park A-team overall survival test is going great.
  • Personally I find the est drug potential on JNJ CC listing for Imetelstat TBA very interesting.....Like an open book with alot of PAGES...ie, for multiple cures...Now that would be well worth the wait....I'm saying PLATFORM DRUG.....JMHO
  • Top 40 Drugs In The Pipeline - Chemical & Engineering News

  • Today will be the last chance to buy GERN under $50.
  • JnJ/Janssen is currently running 205 clinical trials in 1122 locations. JnJ/Janssen ranks Imetelstat in their top 10. Looking Good